Telomir Pharmaceuticals Reports Positive Telomir-1 Results in Triple-Negative Breast Cancer Zebrafish Study

Telomir Pharmaceuticals, a preclinical-stage biotechnology company, has reported positive results from an efficacy study evaluating its lead candidate Telomir-1 in zebrafish tumor xenograft models of triple-negative breast cancer. The study, conducted in collaboration with BioReperia using its ZTX(R) ONCOLEADS platform, demonstrated statistically significant reductions in primary tumor growth and metastatic dissemination in an aggressive TNBC model with limited responsiveness to paclitaxel.

In a separate aggressive TNBC model where paclitaxel showed activity, Telomir-1 achieved comparable tumor growth reduction as a monotherapy and produced greater inhibition when combined with paclitaxel than either agent alone. These findings suggest potential therapeutic benefits for Telomir-1 both as a standalone treatment and in combination with existing chemotherapy agents for difficult-to-treat cancers.

The implications of these results extend beyond the immediate study outcomes. Triple-negative breast cancer represents one of the most challenging forms of breast cancer to treat due to its aggressive nature and limited therapeutic options. The demonstration of Telomir-1's efficacy in models resistant to paclitaxel, a commonly used chemotherapy drug, suggests the compound may offer new hope for patients with treatment-resistant disease.

Telomir-1 represents a novel approach to cancer treatment, designed as a small-molecule therapeutic targeting epigenetic and metabolic drivers of disease. According to the company, the compound has demonstrated activity in preclinical studies involving modulation of DNA and histone methylation, restoration of redox balance, and normalization of cellular function. This mechanism of action distinguishes it from traditional chemotherapy approaches that primarily target rapidly dividing cells.

The study results have broader implications for the biotechnology and pharmaceutical industries, particularly in the development of epigenetic therapies for cancer. As research continues to reveal the importance of epigenetic modifications in cancer development and progression, compounds like Telomir-1 that target these mechanisms may represent the next frontier in oncology therapeutics. The positive results in zebrafish models provide a foundation for further preclinical development and potential future clinical trials.

For investors and stakeholders following the company's progress, these results represent a significant milestone in Telomir Pharmaceuticals' development pipeline. The latest news and updates relating to the company are available in its newsroom at https://ibn.fm/TELO. The study was conducted in collaboration with BioReperia, a company specializing in zebrafish-based drug discovery platforms that offer advantages for early-stage cancer research, including high-throughput screening capabilities and physiological relevance for studying metastasis.

The announcement was made through MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various corporate communications solutions. More information about MissionIR is available at https://www.MissionIR.com, with full terms of use and disclaimers applicable to all content provided by the platform.